{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:39:00Z","timestamp":1790804340296,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116792","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:26:37Z","timestamp":1778757997000},"page":"116792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors"],"prefix":"10.1016","volume":"242","author":[{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9769-0850","authenticated-orcid":false,"given":"Manish R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Seamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew W.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Rodriguez-Freixinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Dozio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri","family":"Tat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Massiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaksandr","family":"Hurynovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokhtar","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-5246","authenticated-orcid":false,"given":"Sandrine","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4723-0550","authenticated-orcid":false,"given":"Anne","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-666X","authenticated-orcid":false,"given":"Esteban","family":"Rodrigo Imedio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":false,"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2026.116792_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116792_bib2","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev Mol Med"},{"issue":"23","key":"10.1016\/j.ejca.2026.116792_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314672","article-title":"DNA damage response in cancer therapy and resistance: challenges and opportunities","volume":"23","author":"Jurkovicova","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ejca.2026.116792_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bjc.6604208","article-title":"G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer","volume":"98","author":"Bucher","year":"2008","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116792_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0092-8674(93)80048-J","article-title":"Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase","volume":"74","author":"Heald","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.str.2004.12.017","article-title":"Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation","volume":"13","author":"Squire","year":"2005","journal-title":"Structure"},{"issue":"2","key":"10.1016\/j.ejca.2026.116792_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"S\u00f8rensen","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2026.116792_bib8","article-title":"Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations","volume":"8","author":"Meng","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejca.2026.116792_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828684","article-title":"Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1","volume":"12","author":"Bukhari","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116792_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038254","article-title":"High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy","volume":"7","author":"Magnussen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2026.116792_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2407-13-288","article-title":"High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients","volume":"13","author":"Magnussen","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116792_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2014.07.102","article-title":"Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions","volume":"135","author":"Slipicevic","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2026.116792_bib13","doi-asserted-by":"crossref","first-page":"49902","DOI":"10.18632\/oncotarget.10231","article-title":"Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"7_ement","key":"10.1016\/j.ejca.2026.116792_bib14","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1538-7445.AM2023-6185","article-title":"Abstract 6185: Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma","volume":"83","author":"Piggott","year":"2023","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2026.116792_bib15","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.116792_bib16","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116792_bib17","unstructured":"Riviere M.K., Ursino M., Andrillon A., Bellon A., Rodrigo Imedio E., Micallef S. U-DESPE: a Utility-based Bayesian approach for dosage optimization relying on Dose-Exposure- Safety\/Pharmacodynamics\/anti-tumor activity relationship modeling for oncology clinical trials. Utrecht, Netherlands; 2023."},{"issue":"6","key":"10.1016\/j.ejca.2026.116792_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"10271","key":"10.1016\/j.ejca.2026.116792_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116792_bib20","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1016\/j.annonc.2024.08.697","article-title":"Abstract 630P: Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)","volume":"35","author":"Gelderblom","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116792_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/705745","article-title":"PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis","volume":"2015","author":"Kumar","year":"2015","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.ejca.2026.116792_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/acschembio.7b00147","article-title":"Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity","volume":"12","author":"Wright","year":"2017","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116792_bib23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41598-018-19573-x","article-title":"PLK1 protects against sepsis-induced intestinal barrier dysfunction","volume":"8","author":"Cao","year":"2018","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.ejca.2026.116792_bib24","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12_ement","key":"10.1016\/j.ejca.2026.116792_bib25","doi-asserted-by":"crossref","first-page":"CT029","DOI":"10.1158\/1538-7445.AM2022-CT029","article-title":"Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC)","volume":"82","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","article-title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","volume":"18","author":"Bauer","year":"2023","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116792_bib27","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116792_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Invest N Drugs"},{"issue":"9","key":"10.1016\/j.ejca.2026.116792_bib29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1124\/dmd.122.000969","article-title":"Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition","volume":"51","author":"Nakada","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.ejca.2026.116792_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-020-03070-0","article-title":"A real or apparent decrease in glomerular filtration rate in patients using olaparib?","volume":"77","author":"Bruin","year":"2021","journal-title":"Eur J Clin Pharm"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib31","first-page":"387","article-title":"Cystatin C: a promising marker and predictor of impaired renal function","volume":"36","author":"Westhuyzen","year":"2006","journal-title":"Ann Clin Lab Sci"},{"issue":"8","key":"10.1016\/j.ejca.2026.116792_bib32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jcph.1844","article-title":"QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019","volume":"61","author":"Cohen-Rabbie","year":"2021","journal-title":"J Clin Pharm"},{"issue":"1","key":"10.1016\/j.ejca.2026.116792_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The Challenges of Predicting Drug-Induced QTc Prolongation in Humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib34","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2020.12.006","article-title":"Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series","volume":"84","author":"Villani","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116792_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/nu15010226","article-title":"Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy-A Narrative Review","volume":"15","author":"Pellegrini","year":"2023","journal-title":"Nutrients"},{"issue":"13 ement","key":"10.1016\/j.ejca.2026.116792_bib36","doi-asserted-by":"crossref","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2021-CT016","article-title":"Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors","volume":"81","author":"Tolcher","year":"2021","journal-title":"Cancer Res"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116792_bib37","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2022.40.16_suppl.5515","article-title":"IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification","volume":"40","author":"Au-Yeung","year":"2022","journal-title":"JCO"},{"issue":"14","key":"10.1016\/j.ejca.2026.116792_bib38","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cjp2.269","article-title":"High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer","volume":"8","author":"Aziz","year":"2022","journal-title":"J Pathol Clin Res"},{"issue":"4","key":"10.1016\/j.ejca.2026.116792_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005120","article-title":"Integrated functional, gene expression and genomic analysis for the identification of cancer targets","volume":"4","author":"Iorns","year":"2009","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.ejca.2026.116792_bib42","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:54:29Z","timestamp":1781153669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S0959804926005733"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116792","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116792"}}